Prescription:-
TC(1378).(01).Cardiology Department Case No (48):-Chronic Coronary Disease (Prescription+Report+Image)
The website currently lists TC(1377) as its most recent Medical Blog entry and Cardiology Case No 47 using category segment (01). Therefore TC(1378), DCS/site segment (01), and Cardiology Case No (48) are PROPOSED next numbers, not reserved or verified after CMS publication. Site: https://raiyyantahsan.com/category/medical-blog/ and https://raiyyantahsan.com/category/cardiology/. [C 0.94 for observation; C 0.78 for future uniqueness]
Diagnosis is NOT confirmed. Doctor’s Dx, C/C, O/E and reports cannot reliably be read. In particular verify medicine #10 and Flutisal strength. Confidence denotes editorial assessment, not measured probability.
1. Patient Profile | রোগীর তথ্য
Age/Sex: 56 years, Male — ছবিতে বয়স ৫৬ এবং M চিহ্নিত [C 0.96].
Prescription date: 14 October 2026 — হাতে লেখা তারিখ সম্ভবত ১৪.১০.২৬ [C 0.84].
Photograph: Only one partially visible prescription image provided; no separate investigation reports [C 0.99].
Privacy: Patient name and identifying handwriting omitted; redact original before public web posting [C 0.99].
2. Prescription Transcription | ওষুধ শনাক্তকরণ
| # | Read from photo | Generic / বাংলায় | Confidence |
|---|---|---|---|
| 01 | Edeloss 20/50 | Furosemide 20 mg + Spironolactone 50 mg (ফিউরোসেমাইড + স্পাইরোনোল্যাকটোন) | 0.94 |
| 02 | Empa 10 | Empagliflozin 10 mg (এম্পাগ্লিফ্লোজিন) | 0.98 |
| 03 | Bislol 2.5 | Bisoprolol fumarate 2.5 mg (বিসোপ্রোলল) | 0.98 |
| 04 | Angilock 50 | Losartan potassium 50 mg (লোসারটান) | 0.97 |
| 05 | Clopid-AS | Clopidogrel 75 mg + Aspirin 75 mg (ক্লোপিডোগ্রেল + অ্যাসপিরিন) | 0.94 |
| 06 | Dextac 30 (probable) | Dexlansoprazole 30 mg (ডেক্সল্যানসোপ্রাজল) — conditional on name verification | 0.76 |
| 07 | Rapasin 8 | Silodosin 8 mg (সিলোডোসিন) | 0.95 |
| 08 | Zolium 0.5 (probable) | Alprazolam 0.5 mg (অ্যালপ্রাজোলাম) — handwritten dose is indistinct; 0.5 mg likely | 0.82 |
| 09 | Angivent MR (strength not written) | Trimetazidine dihydrochloride (ট্রাইমেটাজিডিন); marketed MR tablet is 35 mg; original photograph does not clearly record strength | 0.91 |
| 10 | Unclear word, perhaps “Con… (10)” | NOT VERIFIABLE — অস্পষ্ট; কোনো জেনেরিক অনুমান করা নিরাপদ নয়। | 0.20 |
| 11 | Nidocard Retard 2.6 (probable) | Nitroglycerin 2.6 mg sustained/retard oral tablet (নাইট্রোগ্লিসারিন) | 0.80 |
| 12 | Flutisal ConviCap (strength NOT selected clearly) | Salmeterol 50 mcg + Fluticasone propionate 100/250/500 mcg (স্যালমেটেরল + ফ্লুটিকাসন); exact prescribed strength unclear | 0.86 |
Method: Blue handwriting was interpreted with MedEx verification. Items marked probable remain unsafe for automatic dispensing [C 0.98].
3. C/C, O/E, History and Advice | চিকিৎসকের নথি থেকে
C/C — Chief complaints / প্রধান অভিযোগ: Not reliably legible/explicit; do NOT infer chest pain, dyspnea, leg edema or urinary hesitancy as reported symptoms [C 0.98].
O/E — On examination / শারীরিক পরীক্ষা: No clearly readable BP, pulse, SpO2, lung auscultation, JVP, edema or abdominal findings [C 0.98].
O/H — Occupational/Other history / অন্যান্য ইতিহাস: Not documented or unreadable [C 0.98].
D/H — Disease/Drug history / পূর্ব রোগ ও ওষুধ: Treatment pattern suggests vascular, metabolic and urologic conditions; no past MI, PCI, DM or smoking history formally documented [C 0.93].
M/H — Medication/Medical history / ওষুধ বা চিকিৎসা ইতিহাস: The medicine list is visible; adherence, allergies and previous use are unrecorded [C 0.96].
O/S/E — Other systemic examination / অন্যান্য সিস্টেম পরীক্ষা: Not documented/readable [C 0.98].
O/G/E — Other general examination / সাধারণ পরীক্ষা: Not documented/readable [C 0.98].
Plan / Advice: Handwritten frequencies partially legible only. No safe complete plan, lifestyle advice, or follow-up time can be extracted [C 0.94].
Printed marketing: “Trocer Pump Spray” appears in preprinted/promotional text rather than a clearly written Rx order. Do NOT add Trocer spray as a confirmed prescription medicine [C 0.94].
4. Doctor Dx vs. Evidence | চিকিৎসকের রোগনির্ণয়
Doctor-written Dx: NO CLEAR EXPLICIT DIAGNOSIS FOUND on supplied readable region. “Cardiology” is doctor specialty, not patient diagnosis [C 0.97].
Confirmed clinical diagnoses: NONE can be established from medications alone without original records, physical examination and appropriate tests [C 0.99].
5. Definition & Pathophysiology | সংজ্ঞা ও রোগতত্ত্ব
Chronic coronary disease / দীর্ঘস্থায়ী করোনারি রোগ: Reduced coronary perfusion from atherosclerosis can provoke exertional angina. DAPT/antianginals are clues, NOT tests for coronary stenosis [C 0.70].
Heart failure / হৃদ্যন্ত্রের পাম্পিং বা ফিলিং সমস্যা: Clinical syndrome of symptoms/signs caused by cardiac dysfunction; edema/diuretic alone does not confirm HF or EF subtype [C 0.84].
Benign prostatic hyperplasia / প্রোস্টেট বড় হওয়া: Non-malignant enlargement may cause lower urinary tract symptoms; silodosin use supports symptom-directed therapy but is not pathology proof [C 0.84].
Asthma/COPD / হাঁপানি বা ক্রনিক অবস্ট্রাকটিভ ফুসফুস রোগ: Asthma requires typical variable symptoms plus variable airflow limitation; COPD requires spirometry and compatible exposure/history [C 0.93].
6. Investigations & Report Interpretation | পরীক্ষা
Actually prescribed/attached investigations: No confirmed handwritten investigations and NO report values can be extracted; English result + Bengali result cannot be given without report [C 0.99].
Cardiovascular: BP sitting/standing, HR, ECG, transthoracic echo (EF, wall motion, valve), NT-proBNP if HF suspected; troponin + urgent ECG if acute chest pain. Lipid profile and CBC [C 0.94].
Kidney/electrolytes: Serum creatinine/eGFR, Na+, K+, urea, urine ACR because ARB+spironolactone+loop+SGLT2 risks [C 0.98].
Diabetes: HbA1c and fasting glucose; use ADA laboratory criteria, not medicine-based diagnosis [C 0.97].
Urinary: IPSS symptom score, urine dipstick, abdominal/DRE evaluation; PSA shared decision when indicated; specialist flow rate and post-void residual [C 0.93].
Respiratory: Pre/post-bronchodilator spirometry (FEV1/FVC, reversibility), asthma/COPD symptoms, tobacco/biofuel history and technique review [C 0.96].
7. Prescribed Drug Analysis — MedEx অনুযায়ী | সব ওষুধের ১৬-দফা বিশ্লেষণ
01. Edeloss 20/50 — ইডিলস
1. Generic name / জেনেরিক: Furosemide 20 mg + Spironolactone 50 mg (ফিউরোসেমাইড + স্পাইরোনোল্যাকটোন)
2. Brand name / ব্র্যান্ড: Edeloss 20/50 — ইডিলস
3. MedEx alternate brand: Diretic 20/50; Edemide 20/50; Edenil 20/50
4. MedEx therapeutic class: Potassium-sparing diuretics; Potassium-sparing diuretics & Aldosterone antagonists [MedEx]
5. Pharmacological class: Loop diuretic + mineralocorticoid receptor antagonist (MRA)
6. Use of purpose / উদ্দেশ্য: Edema/volume overload, chronic HF-related congestion; sometimes resistant hypertension/ascites — শরীরে জমে থাকা বাড়তি পানি বের করা।
7. Why doctor may prescribe / সম্ভাব্য কারণ: সম্ভাব্য fluid overload/কনজেশন; রোগীর HF বা edema প্রমাণিত নয়। [C 0.54]
8. Side effects: Dehydration, hypotension, Na/K disturbance, gynecomastia; renal deterioration — পানিশূন্যতা, রক্তচাপ/লবণের সমস্যা।
9. MedEx link: https://medex.com.bd/brands/2865/edeloss-20-mg-tablet
10. Price & other strengths: ৳8.00/unit; ৳80.00/10-tablet strip [MedEx] Edeloss 40 mg+50 mg tablet (৳10/unit, ৳100/strip).
11. Mechanism: Furosemide blocks NKCC2 (thick ascending limb); spironolactone blocks aldosterone receptor (collecting duct) — natriuresis with relative potassium conservation.
12. Indications: CHF congestion, edema, ascites, selected HTN/hyperaldosteronism.
13. Interactions + contraindications: Losartan + spironolactone → hyperkalemia/AKI; SGLT2 inhibitor + loop diuretic → volume depletion; NSAIDs reduce diuresis. Contra: anuria, hyperkalemia, severe renal impairment, Addison disease.
14. Precautions & warnings: Creatinine/eGFR, Na+, K+, weight, BP and dehydration; urinary obstruction with BPH.
15. Dosage & administration: MedEx product range: 1–4 tablets/day response-dependent; PHOTO seems 1–0–0 but NOT confirmed as safe/accurate. Reconcile original.
16. Pregnancy & lactation: Avoid where possible; furosemide/spironolactone require pregnancy risk-benefit review; breastfeeding generally not preferred.
02. Empa 10 — এমপা
1. Generic name / জেনেরিক: Empagliflozin 10 mg (এম্পাগ্লিফ্লোজিন)
2. Brand name / ব্র্যান্ড: Empa 10 — এমপা
3. MedEx alternate brand: Emjard 10; Adempa 10; Ajardy 10
4. MedEx therapeutic class: Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors [MedEx]
5. Pharmacological class: Selective renal SGLT2 inhibitor
6. Use of purpose / উদ্দেশ্য: T2DM glycemic control; established HF or CKD benefit in suitable patients — সুগার নিয়ন্ত্রণ ও হৃদ্যন্ত্র/কিডনি সুরক্ষা।
7. Why doctor may prescribe / সম্ভাব্য কারণ: ডায়াবেটিস, HF অথবা CKD — যেকোনো কারণে হতে পারে; শুধুমাত্র এই ওষুধ দিয়ে T2DM নিশ্চিত করা যায় না। [C 0.52]
8. Side effects: Genital fungal infection, polyuria, dehydration; rare euglycemic DKA.
9. MedEx link: https://medex.com.bd/brands/17133/empa-10-mg-tablet
10. Price & other strengths: ৳25.00/unit; ৳375.00/15-tablet strip [MedEx] Empa 25 mg tablet.
11. Mechanism: Proximal tubular SGLT2 inhibition → urinary glucose/sodium excretion, improved cardio-renal outcomes.
12. Indications: T2DM; guideline-supported HF and CKD use depending on phenotype/eGFR (brand page may list narrower historic indications).
13. Interactions + contraindications: With diuretics → dehydration/hypotension; insulin/secretagogues → low glucose risk. Contra: hypersensitivity; check renal/clinical indication.
14. Precautions & warnings: eGFR/volume status, sick-day pause for acute illness/fasting or surgery per treating team; seek care for vomiting, abdominal pain, rapid breathing (possible euglycemic DKA).
15. Dosage & administration: General starting/maintenance 10 mg once daily; MedEx describes 25 mg titration for glycemic control, but HF/CKD indication and eGFR-specific prescribing differ.
16. Pregnancy & lactation: Avoid during pregnancy and lactation.
03. Bislol 2.5 — বিসলল
1. Generic name / জেনেরিক: Bisoprolol fumarate 2.5 mg (বিসোপ্রোলল)
2. Brand name / ব্র্যান্ড: Bislol 2.5 — বিসলল
3. MedEx alternate brand: Bisocor 2.5; Bisobet 2.5
4. MedEx therapeutic class: Anti adrenergic agent (Beta blockers); Beta-adrenoceptor blocking drugs; Beta-blockers [MedEx]
5. Pharmacological class: Selective β1-adrenergic receptor blocker
6. Use of purpose / উদ্দেশ্য: Hypertension, chronic stable angina, selected stable HFrEF — হৃৎস্পন্দন/চাপ কমানো।
7. Why doctor may prescribe / সম্ভাব্য কারণ: সম্ভাব্য ischemic symptoms/HTN/HF-এর rate and neurohormonal control. [C 0.62]
8. Side effects: Bradycardia, hypotension, fatigue, dizziness, occasional bronchospasm.
9. MedEx link: https://medex.com.bd/brands/2477/bislol-25-mg-tablet
10. Price & other strengths: ৳7.00/unit; ৳98.00/14-tablet strip [MedEx] 1.25, 3.75, 5, 7.5, 10 mg tablets.
11. Mechanism: Blockade of cardiac β1 receptor reduces HR, contractility and renin release.
12. Indications: Hypertension, angina; evidence-based β-blocker for stable HFrEF.
13. Interactions + contraindications: Verapamil/diltiazem/other bradycardic drugs may cause AV block; with nitrate/ARB/diuretics may lower BP. Avoid abrupt stopping.
14. Precautions & warnings: Monitor HR/BP, conduction disease, decompensated HF, bronchospasm/asthma symptoms; pulmonary diagnosis requires check.
15. Dosage & administration: Once daily; indication-based titration, especially HFrEF. Photo appears one dose daily but timing uncertain.
16. Pregnancy & lactation: Use only if indicated under specialist review; breastfeeding requires individualized assessment.
04. Angilock 50 — এনজিলক
1. Generic name / জেনেরিক: Losartan potassium 50 mg (লোসারটান)
2. Brand name / ব্র্যান্ড: Angilock 50 — এনজিলক
3. MedEx alternate brand: Araten 50; Angitan 50; Anreb 50
4. MedEx therapeutic class: Angiotensin-ll receptor blocker [MedEx]
5. Pharmacological class: Angiotensin-II AT1 receptor antagonist (ARB)
6. Use of purpose / উদ্দেশ্য: Hypertension and proteinuric diabetic kidney disease; selected cardiac cases — রক্তচাপ ও কিডনি সুরক্ষা।
7. Why doctor may prescribe / সম্ভাব্য কারণ: সন্দেহিত HTN/diabetes-associated renal risk or cardiac disease. [C 0.69]
8. Side effects: Dizziness, hyperkalemia, creatinine rise, hypotension.
9. MedEx link: https://medex.com.bd/brands/2698/angilock-50-mg-tablet
10. Price & other strengths: ৳10.00/unit; ৳100.00/10-tablet strip [MedEx] 25 mg and 100 mg tablets.
11. Mechanism: AT1 blockade reduces angiotensin II-mediated vasoconstriction and aldosterone signaling.
12. Indications: Hypertension, diabetic kidney disease with albuminuria; selected HF when indicated.
13. Interactions + contraindications: Spironolactone/potassium → hyperkalemia; NSAIDs + diuretic + ARB → AKI; aliskiren with diabetes contraindicated.
14. Precautions & warnings: Serum K+, creatinine/eGFR and BP shortly after start/dose change.
15. Dosage & administration: Common adult HTN initial dose 50 mg daily; adjust by clinical response and renal/volume status.
16. Pregnancy & lactation: Fetotoxic; contraindicated in pregnancy; breastfeeding specialist review.
05. Clopid-AS — ক্লপিড-এএস
1. Generic name / জেনেরিক: Clopidogrel 75 mg + Aspirin 75 mg (ক্লোপিডোগ্রেল + অ্যাসপিরিন)
2. Brand name / ব্র্যান্ড: Clopid-AS — ক্লপিড-এএস
3. MedEx alternate brand: Anclog Plus 75/75; Clocard-A 75/75; Clogfree Plus 75/75
4. MedEx therapeutic class: Anti-platelet drugs [MedEx]
5. Pharmacological class: P2Y12 receptor inhibitor + COX-1 inhibitor (dual antiplatelet therapy, DAPT)
6. Use of purpose / উদ্দেশ্য: After ACS or PCI/stent for a prescribed period; selected other vascular indications — রক্তের প্লেটলেট জমাট কমানো।
7. Why doctor may prescribe / সম্ভাব্য কারণ: Coronary atherothrombosis/ACS/stent HISTORY POSSIBLE, not documented; DAPT itself does NOT prove stent or MI. [C 0.55]
8. Side effects: Bleeding (GI/intracranial), bruising, dyspepsia; rare thrombocytopenia.
9. MedEx link: https://medex.com.bd/brands/3275/clopid-as-75-mg-tablet
10. Price & other strengths: ৳12.04/unit; ৳120.40/10-tablet strip [MedEx] 75 mg+75 mg fixed combination in linked product.
11. Mechanism: Clopidogrel irreversibly blocks platelet ADP P2Y12 activation; aspirin irreversibly blocks COX-1/TXA2.
12. Indications: ACS, post-PCI per cardiology, selected secondary vascular prevention; duration depends on diagnosis/bleeding risk.
13. Interactions + contraindications: NSAIDs, anticoagulants, SSRIs raise bleeding risk; omeprazole/esomeprazole may reduce clopidogrel activation; possible PPI interactions require pharmacist review.
14. Precautions & warnings: Document indication and expected stop/reassessment date; GI bleeding, black stool, hemoptysis, active ulcer; aspirin-induced respiratory disease if history.
15. Dosage & administration: Tablet generally once daily per prescriber; do NOT stop post-stent DAPT or continue lifelong without verification.
16. Pregnancy & lactation: Avoid routine use without specialist assessment; breastfeeding requires individualized advice.
06. Dextac 30 (probable) — ডেক্সট্যাক (সম্ভাব্য)
1. Generic name / জেনেরিক: Dexlansoprazole 30 mg (ডেক্সল্যানসোপ্রাজল) — conditional on name verification
2. Brand name / ব্র্যান্ড: Dextac 30 (probable) — ডেক্সট্যাক (সম্ভাব্য)
3. MedEx alternate brand: Delzo 30; Dexogut 30; Dexoprex 30
4. MedEx therapeutic class: Proton Pump Inhibitor [MedEx]
5. Pharmacological class: Gastric proton-pump (H+/K+-ATPase) inhibitor
6. Use of purpose / উদ্দেশ্য: GERD/erosive esophagitis; sometimes acid suppression alongside DAPT when bleeding risk is present.
7. Why doctor may prescribe / সম্ভাব্য কারণ: Acid suppression / gastroprotection may be intended; no GERD/ulcer history shown. [C 0.46]
8. Side effects: Diarrhea, nausea, abdominal pain; long-term low Mg, B12 issues, infections possible.
9. MedEx link: https://medex.com.bd/brands/28478/dextac-30-mg-ec-capsule
10. Price & other strengths: ৳10.00/unit; ৳100.00/10-capsule strip [MedEx] 60 mg capsule also available.
11. Mechanism: Irreversibly inhibits parietal H+/K+-ATPase → reduces gastric acid production.
12. Indications: Symptomatic GERD, healing/maintenance of erosive esophagitis.
13. Interactions + contraindications: Interacts with gastric pH-dependent medicines, methotrexate, tacrolimus; MedEx includes clopidogrel in interaction list (clinical relevance requires assessment).
14. Precautions & warnings: Long-term PPI use needs indication/periodic review; severe persistent diarrhea or alarm dyspepsia symptoms.
15. Dosage & administration: MedEx: symptomatic non-erosive GERD 30 mg daily (typically 4 weeks), maintenance of healed EE 30 mg daily; not a personal prescription.
16. Pregnancy & lactation: Limited data; use when justified; lactation individualized.
07. Rapasin 8 — র্যাপাসিন
1. Generic name / জেনেরিক: Silodosin 8 mg (সিলোডোসিন)
2. Brand name / ব্র্যান্ড: Rapasin 8 — র্যাপাসিন
3. MedEx alternate brand: Rapiflo 8; Silosin 8; Flowrap 8
4. MedEx therapeutic class: BPH/ Urinary retention/ Urinary incontinence [MedEx]
5. Pharmacological class: Selective α1A-adrenoceptor blocker
6. Use of purpose / উদ্দেশ্য: Moderate/severe male LUTS due to suspected benign prostatic enlargement — প্রস্রাবের পথের বাধাজনিত উপসর্গে সাহায্য।
7. Why doctor may prescribe / সম্ভাব্য কারণ: BPH/LUTS is plausible; voiding symptoms or prostate findings not readable/recorded. [C 0.66]
8. Side effects: Abnormal/retrograde ejaculation, postural dizziness, low BP, diarrhea.
9. MedEx link: https://medex.com.bd/brands/16675/rapasin-8-mg-capsule
10. Price & other strengths: ৳25.00/unit; ৳250.00/10-capsule strip [MedEx] Rapasin 4 mg capsule.
11. Mechanism: Blocks α1A receptors in prostate/bladder neck → smooth muscle relaxation and improved urinary stream.
12. Indications: Symptomatic BPH; not for hypertension.
13. Interactions + contraindications: Strong CYP3A4 inhibitors contraindicated; PDE5 inhibitors and antihypertensives may intensify hypotension.
14. Precautions & warnings: Baseline and standing BP; renal impairment CrCl 30–50 mL/min requires 4mg daily per MedEx; <30 contraindicated. Cataract surgery team must know.
15. Dosage & administration: MedEx: 8 mg orally once daily WITH a meal; adjust for renal function.
16. Pregnancy & lactation: Not indicated for women; lactation not applicable to this patient.
08. Zolium 0.5 (probable) — জোলিয়াম (সম্ভাব্য)
1. Generic name / জেনেরিক: Alprazolam 0.5 mg (অ্যালপ্রাজোলাম) — handwritten dose is indistinct; 0.5 mg likely
2. Brand name / ব্র্যান্ড: Zolium 0.5 (probable) — জোলিয়াম (সম্ভাব্য)
3. MedEx alternate brand: Alprax 0.5; Zolax 0.5; Xanax 0.5
4. MedEx therapeutic class: Benzodiazepine sedatives [MedEx]
5. Pharmacological class: Short-acting benzodiazepine; GABA-A receptor positive allosteric modulator
6. Use of purpose / উদ্দেশ্য: Short-term anxiety/panic symptoms — উদ্বেগ/প্যানিক কমানো।
7. Why doctor may prescribe / সম্ভাব্য কারণ: Anxiety/sleep problems possible; NO psychiatric diagnosis documented. [C 0.36]
8. Side effects: Sedation, impaired coordination, confusion, dependence and withdrawal.
9. MedEx link: https://medex.com.bd/brands/219/zolium-05-mg-tablet
10. Price & other strengths: ৳3.40/unit; ৳34.00/10-tablet strip [MedEx] 0.25 mg tablet; 1 mg and 2 mg XR tablets.
11. Mechanism: Enhances GABA-A-mediated inhibitory neurotransmission.
12. Indications: Anxiety and panic disorder; not a cardiovascular treatment.
13. Interactions + contraindications: Alcohol, opioids, sedatives → additive respiratory depression; may worsen COPD/sleep apnea.
14. Precautions & warnings: Dependence/withdrawal: do not stop abruptly after regular use; avoid driving and unsupervised prolonged use; monitor breathing/sedation.
15. Dosage & administration: Dose individualized by prescriber for shortest useful duration; photo suggests night use but exact instruction not certain.
16. Pregnancy & lactation: Avoid in pregnancy; passes to breastmilk and generally not recommended during lactation.
09. Angivent MR (strength not written) — এনজিভেন্ট এমআর
1. Generic name / জেনেরিক: Trimetazidine dihydrochloride (ট্রাইমেটাজিডিন); marketed MR tablet is 35 mg; original photograph does not clearly record strength
2. Brand name / ব্র্যান্ড: Angivent MR (strength not written) — এনজিভেন্ট এমআর
3. MedEx alternate brand: Angimet MR 35; Cardimet MR 35; Vestar MR 35
4. MedEx therapeutic class: Other Anti-anginal & Anti-ischaemic drugs [MedEx]
5. Pharmacological class: Metabolic anti-ischemic modulator; 3-ketoacyl-CoA thiolase inhibitor
6. Use of purpose / উদ্দেশ্য: Adjunct for stable angina not controlled or intolerant to first-line agents — এনজিনার উপসর্গ কমাতে সহায়ক।
7. Why doctor may prescribe / সম্ভাব্য কারণ: Reinforces suspected chronic ischemic heart symptoms; does not confirm CAD. [C 0.67]
8. Side effects: Dizziness, dyspepsia, nausea; movement disorders/parkinsonism possible.
9. MedEx link: https://medex.com.bd/brands/3133/angivent-mr-35-mg-mr-tablet
10. Price & other strengths: For VERIFIED 35 mg MR product: ৳10.00/unit; ৳100.00/10-tablet strip [MedEx]. Original strength unverified. The named brand appears as 35 mg MR; other trimetazidine brands have 20 mg IR formulations.
11. Mechanism: Metabolic substrate shift from fatty acid oxidation toward glucose oxidation in ischemic myocardium.
12. Indications: Add-on treatment in chronic stable angina; NOT rescue for ACS/MI.
13. Interactions + contraindications: No major established common interactions in MedEx; avoid with movement disorders and severe renal impairment.
14. Precautions & warnings: Contraindicated in Parkinson disease/restless leg symptoms/severe renal impairment; reassess benefit ~3 months.
15. Dosage & administration: For verified MR 35 mg formulation: 35 mg twice daily with meals per MedEx. Handwritten regimen and strength unclear.
16. Pregnancy & lactation: Avoid during pregnancy and breastfeeding due to insufficient data.
10. Unclear word, perhaps “Con… (10)” — নাম অস্পষ্ট
1. Generic name / জেনেরিক: NOT VERIFIABLE — অস্পষ্ট; কোনো জেনেরিক অনুমান করা নিরাপদ নয়।
2. Brand name / ব্র্যান্ড: Unclear word, perhaps “Con… (10)” — নাম অস্পষ্ট
3. MedEx alternate brand: Not provided without exact medicine identification.
4. MedEx therapeutic class: Not verifiable on MedEx.
5. Pharmacological class: Unknown.
6. Use of purpose / উদ্দেশ্য: Unknown — অনুমানযোগ্য নয়।
7. Why doctor may prescribe / সম্ভাব্য কারণ: ব্র্যান্ড/ডোজ স্পষ্ট হলে উদ্দেশ্য বিশ্লেষণ সম্ভব। [C 0.10]
8. Side effects: Unknown.
9. MedEx link: Not linkable safely; verify tablet strip or packaging.
10. Price & other strengths: Unknown; no valid unit/strip price can be assigned. Unknown.
11. Mechanism: Unknown.
12. Indications: Unknown.
13. Interactions + contraindications: Potential interaction review incomplete until this medicine is identified.
14. Precautions & warnings: Pharmacist/doctor should decipher BEFORE dispensing; do not substitute a similarly spelled drug.
15. Dosage & administration: Unknown; cannot transcribe a safe dose.
16. Pregnancy & lactation: Unknown.
11. Nidocard Retard 2.6 (probable) — নিডোকার্ড রিটার্ড (সম্ভাব্য)
1. Generic name / জেনেরিক: Nitroglycerin 2.6 mg sustained/retard oral tablet (নাইট্রোগ্লিসারিন)
2. Brand name / ব্র্যান্ড: Nidocard Retard 2.6 (probable) — নিডোকার্ড রিটার্ড (সম্ভাব্য)
3. MedEx alternate brand: GTN SR 2.6; Nitrin SR 2.6; Anril SR 2.6
4. MedEx therapeutic class: Nitrates: Coronary vasodilators [MedEx]
5. Pharmacological class: Organic nitrate; nitric-oxide donor and vasodilator
6. Use of purpose / উদ্দেশ্য: Angina prophylaxis in coronary disease — বুকে চাপ/ব্যথার আক্রমণ প্রতিরোধ।
7. Why doctor may prescribe / সম্ভাব্য কারণ: Nitrate + trimetazidine + DAPT makes angina/chronic coronary care plausible, not confirmed. [C 0.70]
8. Side effects: Headache, flushing, dizziness, hypotension, tolerance.
9. MedEx link: https://medex.com.bd/brands/3017/nidocard-retard-26-mg-retard-tablet
10. Price & other strengths: ৳5.00/unit; ৳70.00/14-tablet strip [MedEx] 6.4 mg retard; separate 0.5 mg sublingual and 400 mcg/spray preparations are NOT interchangeable.
11. Mechanism: Nitric oxide → guanylate cyclase activation → cGMP↑ → venodilation and reduced preload.
12. Indications: Angina prevention; rescue treatment requires specifically prescribed rapid-acting sublingual preparation.
13. Interactions + contraindications: PDE5 inhibitors (sildenafil/tadalafil/vardenafil) + nitrates → dangerous hypotension; other BP drugs/silodosin add hypotension.
14. Precautions & warnings: Long-acting oral nitrate is NOT rescue for sudden chest pain; check BP and nitrate-free interval as clinically appropriate.
15. Dosage & administration: MedEx example for 2.6 mg retard: one tablet twice daily before meals; actual photo seems daily, cannot resolve. Clinician must verify.
16. Pregnancy & lactation: Use only if clinically necessary; limited lactation safety data.
12. Flutisal ConviCap (strength NOT selected clearly) — ফ্লুটিসাল ইনহেলেশন ক্যাপসুল
1. Generic name / জেনেরিক: Salmeterol 50 mcg + Fluticasone propionate 100/250/500 mcg (স্যালমেটেরল + ফ্লুটিকাসন); exact prescribed strength unclear
2. Brand name / ব্র্যান্ড: Flutisal ConviCap (strength NOT selected clearly) — ফ্লুটিসাল ইনহেলেশন ক্যাপসুল
3. MedEx alternate brand: Flumetol DPI; Protide DPI; Salflu DPI
4. MedEx therapeutic class: Long-acting selective β-adrenoceptor stimulants; Respiratory corticosteroids [MedEx]
5. Pharmacological class: Long-acting β2 agonist (LABA) + inhaled corticosteroid (ICS)
6. Use of purpose / উদ্দেশ্য: Maintenance therapy for asthma or selected COPD — শ্বাসনালির প্রদাহ/সংকোচন নিয়ন্ত্রণ।
7. Why doctor may prescribe / সম্ভাব্য কারণ: Airway disease is possible; asthma/COPD is not documented and cannot be differentiated by medicine alone. [C 0.51]
8. Side effects: Oral thrush/dysphonia, tremor, palpitations; COPD use may increase pneumonia risk.
9. MedEx link: https://medex.com.bd/brands/3944/flutisal-50-mcg-inhalation-capsule
10. Price & other strengths: 50/100: ৳5/unit; ৳30/6-capsule strip. 50/250: ৳12/unit; ৳72/6-capsule strip. 50/500: ৳15/unit (MedEx); price depends on selected strength. DPI capsule strengths 50/100, 50/250, 50/500 mcg; confirm blue tick refers to Flutisal but not clearly exact strength.
11. Mechanism: Salmeterol stimulates β2 bronchodilation; fluticasone activates corticosteroid receptor reducing airway inflammation.
12. Indications: Asthma controller; COPD in selected patients guided by phenotype and exacerbation history.
13. Interactions + contraindications: Potent CYP3A4 inhibitors may increase steroid exposure; β-blockers may antagonize bronchodilation.
14. Precautions & warnings: CAPSULE FOR INHALATION DEVICE — DO NOT SWALLOW; rinse mouth; NOT a rapid rescue inhaler. In asthma, salmeterol/fluticasone is not an as-needed MART reliever.
15. Dosage & administration: For confirmed DPI formulation MedEx: often 1 inhalation twice daily (depends on severity/strength); original handwritten instructions and strength unverified.
16. Pregnancy & lactation: Uncontrolled maternal asthma is also a risk; continuation individualized with maternal-fetal clinician; lactation based on clinical risk-benefit.
Preprinted Trocer Pump Spray is NOT a confirmed Rx order; it is separately listed on MedEx as nitroglycerin 400 mcg/spray.
8. Bangladesh Clinical Practice Medicines | MedEx অনুযায়ী বাংলাদেশে ব্যবহৃত ওষুধ ও দুটি টেবিল
| Disease | Bangladesh brands | Reason | Caveat |
|---|---|---|---|
| Congestion | Edeloss; Diretic; Edemide | Diuretics | HF unconfirmed |
| T2DM/HF/CKD | Empa; Emjard; Adempa | SGLT2 inhibition | Check eGFR/A1c |
| HTN/angina | Bislol; Bisocor; Angilock; Araten | BP/HR control | Depends on phenotype |
| ACS/PCI | Clopid-AS; Anclog Plus | Antiplatelet | Need indication/duration |
| Angina | Angivent MR; Nidocard Retard | Prevention | Not acute rescue |
| LUTS/BPH | Rapasin; Rapiflo | Prostate neck relaxant | Symptom workup |
| Airway | Flutisal; Protide; Salflu | ICS/LABA | Not rescue |
Table A: MedEx-verified class examples; no interchange authorization.
| Medicine | Alternatives | MedEx link | Caution |
|---|---|---|---|
| Edeloss 20/50 | Diretic 20/50; Edemide 20/50; Edenil 20/50 | https://medex.com.bd/brands/2865/edeloss-20-mg-tablet | Verify exact formulation |
| Empa 10 | Emjard 10; Adempa 10; Ajardy 10 | https://medex.com.bd/brands/17133/empa-10-mg-tablet | Verify exact formulation |
| Bislol 2.5 | Bisocor 2.5; Bisobet 2.5 | https://medex.com.bd/brands/2477/bislol-25-mg-tablet | Verify exact formulation |
| Angilock 50 | Araten 50; Angitan 50; Anreb 50 | https://medex.com.bd/brands/2698/angilock-50-mg-tablet | Verify exact formulation |
| Clopid-AS | Anclog Plus 75/75; Clocard-A 75/75; Clogfree Plus 75/75 | https://medex.com.bd/brands/3275/clopid-as-75-mg-tablet | Verify exact formulation |
| Dextac 30 (probable) | Delzo 30; Dexogut 30; Dexoprex 30 | https://medex.com.bd/brands/28478/dextac-30-mg-ec-capsule | Verify exact formulation |
| Rapasin 8 | Rapiflo 8; Silosin 8; Flowrap 8 | https://medex.com.bd/brands/16675/rapasin-8-mg-capsule | Verify exact formulation |
| Zolium 0.5 (probable) | Alprax 0.5; Zolax 0.5; Xanax 0.5 | https://medex.com.bd/brands/219/zolium-05-mg-tablet | Verify exact formulation |
| Angivent MR (strength not written) | Angimet MR 35; Cardimet MR 35; Vestar MR 35 | https://medex.com.bd/brands/3133/angivent-mr-35-mg-mr-tablet | Verify exact formulation |
| Unclear word, perhaps “Con… (10)” | Not provided without exact medicine identification. | Not linkable safely; verify tablet strip or packaging. | Verify exact formulation |
| Nidocard Retard 2.6 (probable) | GTN SR 2.6; Nitrin SR 2.6; Anril SR 2.6 | https://medex.com.bd/brands/3017/nidocard-retard-26-mg-retard-tablet | Verify exact formulation |
| Flutisal ConviCap (strength NOT selected clearly) | Flumetol DPI; Protide DPI; Salflu DPI | https://medex.com.bd/brands/3944/flutisal-50-mcg-inhalation-capsule | Verify exact formulation |
Table B: brand examples, not a dosing/substitution order.
Scope: Class-based MedEx-verified examples are descriptive examples, NOT recommendations to combine or substitute [C 0.99].
9. My Clinical Working Assessment | আমার প্রাথমিক ক্লিনিক্যাল মূল্যায়ন
Provisional Dx / অনুমানভিত্তিক নির্ণয়
Suspected Chronic Coronary Disease / Chronic Coronary Syndrome (unconfirmed); evaluate angina phenotype, history of ACS/PCI, HTN, possible cardiac congestion or HF. বাংলা: সম্ভাব্য দীর্ঘস্থায়ী করোনারি হৃদ্রোগ; রোগীর উপসর্গ ও পরীক্ষায় নিশ্চিত নয়। [C 0.68]
Specialist Referral / বিশেষজ্ঞের কাছে পাঠানো
Cardiology specialist / হৃদ্রোগ বিশেষজ্ঞ first; evaluate DAPT rationale, ECG, echo, symptom characterization. Secondary referrals by objective findings: urology / pulmonology / diabetes care. [C 0.97]
Clinical Diagnostic Conclusion / রোগনির্ণয়ের উপসংহার
Article TOPIC is Chronic Coronary Disease by editorial choice, NOT a chart-confirmed diagnosis. No explicit doctor-written Dx, angina symptom narrative, ECG/echo/coronary report, or verified vitals supplied. Dx remains provisional pending examination and reports. বাংলা: শিরোনামে রোগের নাম থাকলেও এটি নিশ্চিত রোগনির্ণয় নয়। [C 0.99]
Working cluster A: Suspected chronic coronary disease / stable angina treatment context — possible, NOT confirmed (C 0.68). Nitrate, trimetazidine and DAPT suggest this most strongly.
Working cluster B: Possible hypertension and/or cardiac congestion / HF (C 0.53). Losartan+bisoprolol+diuretic may reflect HTN, HF, or volume overload from another cause.
Working cluster C: Possible type 2 diabetes versus empagliflozin used primarily for HF/CKD (C 0.49); no HbA1c or documented D/H.
Working cluster D: Male LUTS likely managed as possible BPH (C 0.67), not confirmed by DRE/uroflow.
Working cluster E: Obstructive airway disease requiring ICS/LABA possible: asthma vs COPD undetermined (C 0.52).
Working cluster F: Anxiety/sleep disorder not established despite likely alprazolam (C 0.31).
Diagnostic ceiling: No definitive final diagnosis can be ethically justified from this photo alone [C 0.99].
10. Doctor’s Dx vs My Dx | চিকিৎসকের ও আমার নির্ণয়ের তুলনা
| Comparison | Doctor evidence | My impression | Meaning |
|---|---|---|---|
| Coronary | No clear Dx | Possible CCD/angina C 0.68 | Compatibility only |
| Heart failure | No EF | Possible C 0.53 | Not confirmed |
| Diabetes | No lab Dx | Possible T2DM vs HF/CKD C 0.49 | Not confirmed |
| Urologic | No symptom | Likely BPH-LUTS C 0.67 | Clue only |
| Lung | No spirometry | Asthma/COPD possible C 0.52 | Undifferentiated |
GREEN — Similarity / মিল: Both original specialist context and verified drug groups point toward cardiovascular management; this is compatibility of treatment pattern ONLY, NOT a match of documented diagnoses [C 0.72].
ORANGE — Dissimilarity / অমিল: Doctor’s explicit Dx absent; independent labels are DIFFERENTIALS rather than alternative confirmed diagnoses. Exact “similar/dissimilar” diagnostic agreement cannot be assessed [C 0.99].
Key failure mode: Assuming the patient definitely has MI/stent/HFrEF/T2DM/COPD based on prescriptions would be an unsupported leap [C 0.99].
11. Differential Diagnosis | বিকল্প রোগনির্ণয়
Cardiac: Chronic stable angina vs prior ACS/PCI follow-up vs microvascular angina; if acute chest pain rule out ACS [C 0.65].
Edema: HF vs chronic kidney disease vs liver disease vs venous edema (no findings to adjudicate) [C 0.50].
Dyspnea: HF vs asthma vs COPD vs anemia; dyspnea itself not documented [C 0.58].
Urinary: BPH vs urinary infection, detrusor dysfunction, urethral stricture or medication-associated frequency [C 0.69].
12. Management & Guideline Integration | চিকিৎসা-পর্যালোচনা
Coronary: Confirm chest pain phenotype and indication for DAPT. Chronic coronary disease management usually includes event-preventive lipid lowering where appropriate; an ambiguous 10 mg drug must not be assumed to be a statin [C 0.92].
Possible HF: Do not label HFrEF/HFpEF without echocardiography; optimize treatment according to EF and hemodynamics. Check volume status and renal labs before changing doses [C 0.98].
Possible diabetes: Use HbA1c/FPG criteria; empagliflozin may reflect cardio-renal protection even without diabetes [C 0.95].
Respiratory: Verify inhalation capsule strength and device; rinse after dose, do not swallow capsule or use salmeterol/fluticasone as emergency reliever; consider β-blocker respiratory tolerance [C 0.98].
BPH: Document urinary symptom score and red flags; silodosin may contribute to orthostasis with nitrates/antihypertensives [C 0.96].
Medication reconciliation: DO NOT stop/change any ongoing medication solely from this review; verify the handwritten 10-mg medicine and all dosing with prescriber/pharmacist [C 0.99].
13. High-priority Safety Audit | জরুরি নিরাপত্তা
VERY IMPORTANT 1: Spironolactone + losartan increases potassium/renal risk; furosemide + empagliflozin + nitrate + silodosin can lower intravascular volume/BP [C 0.98].
VERY IMPORTANT 2: Clopidogrel + aspirin can cause serious bleeding. Verify PCI/ACS history, indication, DAPT end date and PPI appropriateness [C 0.98].
VERY IMPORTANT 3: Nitrate + sildenafil/tadalafil can cause life-threatening hypotension; distinguish sustained-release tablet from emergency sublingual spray [C 0.99].
VERY IMPORTANT 4: Trimetazidine is not rescue therapy for MI/unstable angina. Unknown 10 mg tablet must be identified [C 0.99].
VERY IMPORTANT 5: Salmeterol/fluticasone DPI is inhaled, never swallowed. Salmeterol is not a rapid reliever; consider rescue plan per GINA/GOLD [C 0.98].
VERY IMPORTANT 6: If ongoing chest pain, severe breathlessness, syncope, black stool/major bleed, anuria or acute urinary retention: emergency care now [C 0.98].
14. Referral | কোন বিশেষজ্ঞের কাছে পাঠাব?
First: Cardiologist / হৃদরোগ বিশেষজ্ঞ — priority to confirm coronary disease, DAPT indication and possible HF phenotype [C 0.98].
Additional: Internal Medicine / Endocrinology if elevated HbA1c; Pulmonologist if wheeze/obstruction; Urologist for LUTS or retention; Nephrologist for renal impairment/hyperkalemia [C 0.92].
15. Clinical Dx Note & Demonstration — NOT a live prescription | ডেমো
Working clinical Dx note (safe language): “Cardiovascular disease under treatment; suspected chronic coronary syndrome/angina (unconfirmed), possible HTN/volume overload/HF; possible diabetes/cardiorenal indication; LUTS likely BPH; possible obstructive airway disease. Confirmation pending ECG/ECHO/renal labs/HbA1c/spirometry and clinical review.” [C 0.95 for faithful uncertainty]
Example chart header: 56/M | Date 14-10-2026 | C/C: not elicited in available record | O/E: no verified vitals | Doctor Dx: not visible | Allergy: unknown | Prior PCI: unknown.
Example Rx reconciliation: List copied from photo only: Edeloss 20/50; Empa 10; Bislol 2.5; Angilock 50; Clopid-AS; Dextac 30?; Rapasin 8; Zolium 0.5?; Angivent MR (strength?); [unreadable] 10; Nidocard Retard 2.6?; Flutisal strength?. NO dose authorization; obtain signed original and clinician confirmation.
Prescribing disclaimer: This demonstration is an educational medication-reconciliation note, not a signed/valid new prescription, and does not add therapies/doses [C 1.00].
16. Overview / Summary & Actionable Plan | সারসংক্ষেপ ও করণীয়
Overview: This looks like complex cardiovascular-centric polypharmacy with possible urologic and pulmonary treatment. No symptoms, exam, lab report or explicit physician diagnosis can be verified [C 0.95].
Step 1 (today): Obtain a sharp full original prescription plus medication strips. Confirm item 10, Flutisal strength, Dextac and Nidocard formulations, all frequencies, allergy, smoking and PCI history.
Step 2 (priority): Review BP/HR/orthostatic BP, SpO2, congestion signs; request creatinine/eGFR, Na/K, CBC, HbA1c, urine ACR and ECG. Echo/NT-proBNP if HF suspected.
Step 3 (targeted): Assess chest pain/stent/DAPT duration; urinary IPSS/dipstick; spirometry for asthma vs COPD; correct inhaler technique.
Step 4 (medication safety): Specialist medication reconciliation; never stop antiplatelets or benzodiazepine abruptly without advice. Emergency assessment for red flags.
Step 5 (follow-up): Record one confirmed diagnosis per supported evidence and revisit provisional list after tests.
17. Reference List | Textbooks, Guidelines and DOI
Textbooks (chapter without unverifiable pages): Harrison’s Principles of Internal Medicine, 22nd ed: chronic coronary syndromes, heart failure, diabetes mellitus, COPD and lower urinary tract symptoms chapters; Davidson’s Principles & Practice of Medicine, 24th ed: cardiovascular/respiratory/endocrine disorders; Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed: diuretics, renin-angiotensin drugs, antiplatelets, nitrates and autonomic pharmacology; Katzung Basic & Clinical Pharmacology, 16th ed: related drug classes. Chapter/page numbers may vary by print/eBook and are not asserted.
AHA/ACC/HFSA 2022 HF guideline: Heidenreich et al. Circulation. 2022;145:e895–e1032. DOI 10.1161/CIR.0000000000001063; https://pubmed.ncbi.nlm.nih.gov/35363499/
2023 Chronic Coronary Disease guideline: Virani et al. J Am Coll Cardiol. 2023. DOI 10.1016/j.jacc.2023.04.003; https://www.jacc.org/guidelines/chronic-coronary-disease
ESC 2023 HF update: McDonagh et al. Eur Heart J. 2023;44:3627–3639. DOI 10.1093/eurheartj/ehad195.
NICE HF: NICE NG106: Chronic heart failure in adults, updated 2025; https://www.nice.org.uk/guidance/ng106/chapter/recommendations
NICE male LUTS: NICE CG97, 2010, update 2015; https://www.nice.org.uk/guidance/cg97/chapter/recommendations
GINA: Global Initiative for Asthma, 2026 Summary Guide; https://ginasthma.org/2026-gina-summary-guide/
GOLD: Global Initiative for Chronic Obstructive Lung Disease, GOLD 2026 report/pocket guide; https://goldcopd.org/2026-gold-report-and-pocket-guide/
ADA 2026: Standards of Care in Diabetes 2026, Section 2. DOI 10.2337/dc26-s002; Section 11 DOI 10.2337/dc26-s011.
MedEx verification: Individual direct MedEx links are provided below each drug; prices are online listed prices, subject to change. MedEx therapeutic-class labels are reproduced verbatim when available; pharmacological class is separately interpreted.
Evidence boundary: Cross-checking online MedEx product pages does not authenticate the source handwritten prescription or prove any clinical diagnosis.
Author: Md.Rafiqul Islam Lipu | Date: Friday, 16 October 2026 | Time: 07:03 PM Asia/Dhaka